Skip to content

Efficacy evaluation of Probucol in combination with atorvastatin in the treatment of acute ischemic stroke - a randomized controlled trial

Efficacy evaluation of probucol combined with atorvastatin in the treatment of acute ischemic stroke

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040461
Enrollment
Unknown
Registered
2020-11-28
Start date
2020-12-01
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke

Interventions

Group 1:Probucol combined with atorvastatin
Group 2:Atorvastatin therapy

Sponsors

Affiliated Hospital of Chengde Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The patient is first onset (or previous history of cerebral infarction, TIA, mRS score 0-1 points) was confirmed by head CT or MRI; 2. According to the diagnostic criteria of acute ischemic stroke, it was confirmed as atherosclerotic cerebral infarction; The onset time was within 48h, the onset age was less than 80 years old, and the patients did not take lipid-regulating drugs within 1 month; 3. Patients willing to cooperate, good compliance.

Exclusion criteria

Exclusion criteria: 1. Previous history of intracranial space-occupying disease, stroke, intracranial arteritis and hypertensive encephalopathy; 2. Patients with malignant tumors; 3. Severe infection or inflammation, severe liver or kidney dysfunction, severe anemia, and severe coagulation dysfunction; 4. Women during pregnancy and lactation; 5. The patient has received treatment before admission and has taken lipid-regulating drugs within 1 month; 6. Patients with severe dementia or severe mental disorder who unable to complete the detection.

Design outcomes

Primary

MeasureTime frame
Serum Oxidized low density lipoprotein (OX-LDL);Serum Oxidized low density lipoprotein (OX-LDL);Marixmeralloproteinase-9 (MMP-9);F2-ISoprpstanes;Carotid intima intima thickness;Vulnerable plaque;

Secondary

MeasureTime frame
Intima plaque area;

Countries

China

Contacts

Public ContactYu Ning

Affiliated Hospital of Chengde Medical University

laura_lover@qq.com+86 0314 2270370

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026